Share ownership Bolt Biotherapeutics, Inc.

BOLT

US0977022039

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 13/06/2026 am IST			5-day change	1st Jan Change
4.560 ^USD	-4.40%		0.00%	-16.61%

13/05	Bolt Biotherapeutics reports first quarter 2026 financial results	RE
13/05	Bolt Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Share class: Bolt Biotherapeutics, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	19,21,567	17,84,928 ( 92.89 %)	0	92.89 %

Major shareholders: Bolt Biotherapeutics, Inc.

Name	Stocks	%	Valuation
Sofinnova Investments, Inc. 7.167 %	1,37,721	7.167 %	723 035 $
Renaissance Technologies LLC 4.019 %	77,225	4.019 %	405 431 $
Vivo Capital LLC 3.768 %	72,414	3.768 %	380 174 $
Pivotal Bioventure Partners Investment Advisor LLC 3.738 %	71,831	3.738 %	377 113 $
T3 Companies LLC 1.978 %	38,000	1.978 %	199 500 $
Board of Trustees of the Leland Stanford Junior University 1.872 %	35,977	1.872 %	188 879 $
TORAY INDUSTRIES, INC. 1.867 %	35,875	1.867 %	188 344 $
PFIZER INC. 1.629 %	31,305	1.629 %	164 351 $
Lynx1 Capital Management LP 1.603 %	30,800	1.603 %	161 700 $
Geode Capital Management LLC 1.498 %	28,791	1.498 %	151 153 $
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	23.97%
Others	6.31%
Toray Industries, Inc.	1.87%
Pfizer Inc.	1.63%
Individuals	0.22%
Unknown	66%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	30.14%
Japan	1.87%
Puerto Rico	1.6%
Individuals	0.22%
United Kingdom	0.17%

Based on 1000 largest holdings

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Companyâ€™s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Companyâ€™s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.

Employees

Sector

Biotechnology & Medical Research

More about the company